Article Text
Abstract
Introduction Identifying behavioural factors related to tobacco may provide a better understanding of what drives this behaviour and thus may inform more effective tobacco control programmes and policies. In this study, we explore associations between behavioural factors (time preferences, risk-taking, general self-efficacy and grit) and tobacco and e-cigarette use among adults.
Methods 4084 adults in the Smoking and Lifestyles in Israel study (2020) were examined. Multivariable logistic regression was used to estimate the association between behavioural factors and the following tobacco and e-cigarette use variables: factory-made cigarettes (FMC), roll-your-own (RYO) cigarettes, water pipes, e-cigarettes and heated tobacco products (HTPs). Dual use of combustible cigarettes and water pipes, combustible cigarettes and e-cigarettes, and combustible cigarettes and HTPs was also examined.
Results Multivariable models revealed that impatient time preferences were significantly associated with higher odds of FMC, RYO and e-cigarette use (FMC: OR=1.68, 95% CI 1.32, 2.13; RYO: OR=1.40, 95% CI 1.00, 1.96; e-cigarettes: OR=1.93, 95% CI 1.14, 3.29) but not water pipes or HTPs. Higher risk-taking scores were associated with increased use of all tobacco products (eg, HTPs: OR=1.20; 95% CI 1.10, 1.32). Higher general self-efficacy was related to lower use of RYO (OR=0.82; 95% CI 0.69, 0.97), e-cigarettes (OR=0.46; 95% CI 0.35, 0.60) and HTPs (OR=0.32; 95% CI 0.24, 0.42). Increased general self-efficacy was also related to lower odds of dual use of all products, while impatience and higher risk-taking were associated with higher odds of dual use of all products. Grit was unrelated to the use of any product.
Conclusions Risk-seeking and impatient preferences appear to increase the likelihood of using various tobacco products and e-cigarettes, whereas higher general self-efficacy appears as protective. These behavioural factors should be considered when designing interventions alongside evidence-based policies.
- Economics
- Global health
- Prevention
Data availability statement
No data are available. SALI study data are not publicly available. A scientific data request may be submitted to the Kenneth H Cooper Institute’s Scientific Review Board Committee for review. The Committee meets regularly to assess the merits of all requests.
Statistics from Altmetric.com
Data availability statement
No data are available. SALI study data are not publicly available. A scientific data request may be submitted to the Kenneth H Cooper Institute’s Scientific Review Board Committee for review. The Committee meets regularly to assess the merits of all requests.
Footnotes
Contributors KS wrote the first draft. QL conducted the statistical analyses. All authors (KS, QL, CM, CS, TL, BMF, MQ, JD) were involved in conceptualisation, methodology, and writing—review and editing. KS is the guarantor.
Funding The study was supported by the American Cancer Society (contract number: 63313).
Disclaimer The views expressed in this study are those of the authors and do not necessarily represent the American Cancer Society or the American Cancer Society–Cancer Action Network.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.